ICYMI: Drug Topics September/October 2024 Issue

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

John Riggi, national advisor for cybersecurity and risk at the American Hospital Association, discusses how pharmacists can assess their store’s vulnerability to cyberattacks.

Researchers conduct a review to understand the efficacy and safety of topical minocycline for the treatment of moderate to severe papulopustular rosacea.

LucyRx is empowering pharmacists and impacting patients’ health outcomes with its business model unlike other market-leading pharmacy benefit managers.

The recommendation includes patients 12 years and older traveling to a country where there is a chikungunya outbreak or where there is an elevated risk for US travelers.

This white paper will examine some common—and costly—assumptions about vendor compliance. We’ll show that pharmacies must do more than meet the bare minimum to stay competitive. We’ll also discuss solutions that pharmacies can leverage to optimize compliance, drive savings from their primary vendor, unlock additional pharmacy savings and enhance purchasing.